<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040144</url>
  </required_header>
  <id_info>
    <org_study_id>ACH443-005</org_study_id>
    <nct_id>NCT00040144</nct_id>
  </id_info>
  <brief_title>Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of 12 Weeks Oral Treatment With ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achillion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achillion Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and antiviral HBV activity of ACH126,
      433 (b-L-Fd4C) in the treatment of adults with lamivudine-resistant chronic Hepatitis B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of safety and antiviral activity of 3 dose levels of ACH126, 443 over a twelve
      week treatment in the population described.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Safety concerns
  </why_stopped>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">May 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>85</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH126, 433 (b-L-Fd4C)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Adults ≥ 18 years of age

          -  Chronic HBV infection, known to be HbsAg positive ≥ 6 months

          -  On lamivudine, either 100 or 150 mg daily for the treatment of chronic hepatitis B
             infection and

          -  Exhibit a 2-3 log decrease in HBV DNA levels followed by a rebound of at least 1.5 log
             HBV DNA or

               -  Achieved an HBV DNA level of &lt;10,000 copies/mL HBV DNA on at least 2 occasions
                  and have rebounded to &gt; 100,000 copies/mL HBV DNA, or

               -  Have a demonstrable 3TC resistant genotype regardless of treatment history.

          -  HBeAG positive

          -  HIV negative

          -  Serum ALT ≥1.5 and ≤10x times upper limit of normal

          -  HGB ≥10g/dl or HCT ≥30% (in the absence of blood transfusions or erythropoietin
             treatment in the preceding two weeks)

          -  Platelet count &gt;75,000/mm(^3), (in the absence of ongoing G-CSF therapy)

          -  Serum creatinine &lt;1.1 times upper limit of normal (ULN)

          -  Negative radiologic screening test (ultrasound, CT scan or MRI) for hepatocellular
             carcinoma (HCC) within 6 months prior to entry

          -  PT/INR&lt;2

          -  Subjects of reproductive capability must utilize an approved forms of birth control

          -  All women of child-bearing capability must have a negative serum or urine pregnancy
             test (minimum sensitivity of 24 IU/L of b-HCG) within 72 hours prior to the start of
             study medication

          -  Subjects must be able to provide written informed consent

          -  Subject must be available for follow-up for a period of 20 weeks

        Exclusion Criteria

          -  HIV infection

          -  Hepatitis C co-infection

          -  Alcohol abuse

          -  Pregnancy or breast-feeding

          -  Inability to tolerate oral medication

          -  Any clinical condition or prior therapy that, in the Investigator's opinion, would
             make the subject unsuitable for the study or unable to comply with the dosing
             requirements

          -  Use of any investigational drug

          -  Patients with decompensated liver disease

          -  Use of any concomitant herbal treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California-Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntington Memorial Hospital</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California-San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-7323</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Weill Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Universtiy Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Infectious Disease Associates, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Research</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unviversity of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong SAR</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.achillion.com</url>
  </link>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2002</study_first_submitted>
  <study_first_submitted_qc>June 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2002</study_first_posted>
  <last_update_submitted>August 18, 2009</last_update_submitted>
  <last_update_submitted_qc>August 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2009</last_update_posted>
  <keyword>E-Antigen positive,</keyword>
  <keyword>Lamivudine-Resistant Chronic Hepatitis B,</keyword>
  <keyword>Achillion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

